Cell Expansion Market Current Trends, Research Analysis And Statistics Released In Latest Report
Cell expansion is
the large scale artificial production of daughter cells from a single
cell, to support medical research. Rising preference for regenerative
medicines offering faster results, and emergence of cell-based
therapies with high patient compatibility are expected to fuel the
cell expansion market during the forecast period (2017–2025).
Regenerative medicine helps the body to form new functional tissue to
replace defective or lost ones providing treatment for conditions
with inadequate therapies. According to the U.S. Department of Health
and Services, in 2016, NIH invested around US$ 1.5 billion in stem
cell research projects. Increasing government and private sector
expenditure on cell-based research therapies is expected to boost
growth of the market for cell expansion in the near future. The
number of FDA approvals for clinical trials of stem cell-based
treatments is rapidly increasing. According to a report published by
Pharmaceutical Research and Manufacturers of America, in 2013, around
69 cell therapies with clinical trials were under review with the
FDA.
Get A Sample Copy
Of This Research Report:
www.coherentmarketinsights.com/insight/request-sample/1293
Key players
operating in the cell expansion market include Becton, Dickinson and
Company, Beckman Coulter, Inc., Corning, Inc., GE Healthcare, Lonza,
Merck KGaA (Sigma-Aldrich Co. LLC), Miltenyi Biotec, Thermo Fisher
Scientific, Inc., Terumo BCT, Inc., and Stemcell Technologies, Inc.
In July 2016, GE Healthcare acquired Biosafe SA, a Swiss company that
manufactures instruments that recover stem cells and help in various
other cell processing procedures related to personalized medicine.
This acquisition will help GE Healthcare to grow the cells in the
sample for appropriate dose sizes.
Increasing
incidence of chronic medical conditions is expected to boost growth
of the cell expansion market over the forecast period
The increasing cases
of chronic and rare medical conditions around the world is another
key factor driving demand for cell expansion. For instance, according
to World Health Organization (WHO), around 15 million people are
projected to suffer from cancer by 2020. The rising prevalence of
cancer, is in turn, expected to boost growth of the cell expansion
market. Cell-based therapy is also a promising approach for treating
chronic kidney disease and is presently the focus of preclinical
studies. Recent advancements in regenerative medicine and tissue
engineering have created cell-based approaches for the treatment of
renal failure. Such treatments include biotechnological approach
using implantation of bioengineered kidney constructs, transplanting
cells, and bio-artificial renal systems.
The number of FDA
approvals for clinical trials of stem cell-based treatments is
rapidly increasing. According to a report published by Pharmaceutical
Research and Manufacturers of America, in 2013, around 69 cell
therapies with clinical trials were under review with the FDA. The
therapeutic classes represented in these trials include skin
diseases, cardiovascular diseases, transplantations, eye conditions,
cancer and associated conditions, musculoskeletal disorders, genetic
disorders, and digestive disorders.
According to the
U.S. Department of Health and Services, in 2016, NIH invested around
US$ 1.5 billion in stem cell research projects. Increasing government
and private sector expenditure on cell-based research therapies is
expected to boost growth of the market for cell expansion in the near
future. The number of FDA approvals for clinical trials of stem
cell-based treatments is rapidly increasing. According to a report
published by Pharmaceutical Research and Manufacturers of America, in
2013, around 69 cell therapies with clinical trials were under review
with the FDA.
Click To Read More On Cell
Expansion Market
Also, Coherent
Market Insights has a proprietary database of pipeline biologics and
biosimilars, called PHASE-XS. This database provides analytical data
in addition to the clinical information of ongoing trials for
biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database, kindly click on the
below link or contact at sales@coherentmarketinsights.com
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment